Krystal Biotech, Inc. (KRYS) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KRYS Revenue Growth
KRYS Revenue Analysis (2016–2025)
As of May 8, 2026, Krystal Biotech, Inc. (KRYS) generated trailing twelve-month (TTM) revenue of $417.3 million, reflecting explosive growth of +31.9% year-over-year. The most recent quarter (Q1 2026) recorded $116.4 million in revenue, up 8.6% sequentially.
Looking at the longer-term picture, KRYS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $389.1 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY), KRYS has outperformed the peer group in terms of revenue growth. Compare KRYS vs RARE →
KRYS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KRYSCurrent | $417M | +31.9% | - | 41.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
KRYS Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $389.1M | +33.9% | $360.4M | 92.6% | $161.3M | 41.5% |
| 2024 | $290.5M | +473.0% | $270.5M | 93.1% | $65.7M | 22.6% |
| 2023 | $50.7M | - | $47.6M | 93.9% | $-109,727,000 | -216.4% |
| 2022 | $0 | - | $0 | - | $-145,196,000 | - |
| 2021 | $0 | - | $0 | - | $-68,275,000 | - |
| 2020 | $0 | - | $-1,851,000 | - | $-32,999,000 | - |
| 2019 | $0 | -100.0% | $-974,000 | - | $-22,081,000 | - |
| 2018 | $1.0M | - | $886K | 86.3% | $-11,916,000 | -1160.3% |
| 2017 | $0 | - | $-23,000 | - | $-4,772,000 | - |
| 2016 | $0 | - | $-2,000 | - | $-1,143,000 | - |
See KRYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KRYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KRYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
Is KRYS's revenue growth accelerating or slowing?
KRYS revenue is accelerating at +31.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $417M. Growth momentum has increased versus prior periods.
What is KRYS's long-term revenue growth rate?
Krystal Biotech, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +31.9% is above this long-term average.
How is KRYS's revenue distributed by segment?
KRYS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.